Trabajos publicados derivados de EB-DERMA:

​

1) Arriba MC, Fernández G, Chacón-Solano E, Martínez-Santamaría L, Illera N, Carrión R, Martín M, Larcher F, González V, Del Río M, Carretero M. Formyl Peptide Receptor 2 DNA aptamers for targeted therapy of wound repair. J Invest Dermatol. 2022 142(8):2238-2248.e8. PMID: 34979109.

IF (2022): 6,5  Q1 (D1) Dermatology (6/70)

e-archivos UC3M: https://researchportal.uc3m.es/display/act555017

Open Access: https://www.sciencedirect.com/science/article/pii/S0022202X21026889?via%3Dihub

 

2) Chacón-Solano E, León C, Carretero M, García M, Sánchez-Domínguez R, Quero F, Méndez-Jiménez E, Bonafont J, Ruiz-Mezcua B, Escámez MJ, Larcher F, Del Río M. Mechanistic interrogation of mutation-independent disease modulators of RDEB identifies the small leucine-rich proteoglycan PRELP as a TGF-β antagonist and inhibitor of fibrosis. Matrix Biol. 2022. 111:189-206. PMID: 35779740.

IF (2022): 6,9  Q1 Biochemistry & Molecular Biology (48/285)

Open Access: https://www.sciencedirect.com/science/article/pii/S0945053X22000877

e-archivos UC3M: https://e-archivo.uc3m.es/handle/10016/38216

 

3) Sacedón R, de Arriba MC, Martínez-Santamaría L, Maseda R, Herráiz-Gil S, Jiménez E, Rosales I, Quintana L, Illera N, García M, Butta N, Fernández-Bello I, Lwin SM, Fernández-Arquero M, León C, McGrath JA, Vicente MA, del Río M, de Lucas R, Sánchez-Ramón S and Escámez MJ, Gluten-sensitive Enteropathy in Recessive Dystrophic Epidermolysis Bullosa. British Journal of Dermatology, 2023; ljad313.

IF (2022): 10,3  Q1 (D1) Dermatology (3/70)

 

4) Herráiz-Gil S, de Arriba MC, Escámez MJ, León C. Multi-Omic data integration in food science and analysis. Current Opinion in Food Science, 2023, 101049, ISSN 2214-7993. https://doi.org/10.1016/j.cofs.2023.101049.

IF (2022): 9,9  Q1 (D1) Food Science & Technology (7/142)

Open Access: https://www.sciencedirect.com/science/article/pii/S2214799323000632

​

 

​

 

Otras publicaciones 

 

1) South AP, Laimer M, Gueye M, Sui JY, Eichenfield LF, Mellerio JE, Nyström A.J. Type VII Collagen Deficiency in the Oncogenesis of Cutaneous Squamous Cell Carcinoma in Dystrophic Epidermolysis Bullosa. Invest Dermatol. 2023 Nov 143(11):2108-2119. doi: 10.1016/j.jid.2023.05.024. PMID: 37327859.

IF (2022): 6,5 Q1  Dermatology (6/70)

Open Access: https://www.sciencedirect.com/science/article/pii/S0022202X23023382?via%3Dihub

 

2) Hou PC, Del Agua N, Lwin SM, Hsu CK, McGrath JA. Innovations in the Treatment of Dystrophic Epidermolysis Bullosa (DEB): Current Landscape and Prospects. Ther Clin Risk Manag. 2023 Jun 14;19:455-473. doi: 10.2147/TCRM.S386923. eCollection 2023.PMID: 37337559.

IF (2022): 2,8 Q3  Health Care Sciences & Services (57/106)

Open Access: https://www.dovepress.com/getfile.php?fileID=90424

 

3) García-Espinosa L, Del Rosal T, Quintana L, Maseda R, Grasa C, Falces-Romero I, Menéndez-Suso JJ, Pérez-Conde I, Méndez-Echevarría A, Aracil Santos FJ, Alonso LA, de Lucas R, Calvo C, Baquero-Artigao F. Bloodstream Infection in Children With Epidermolysis Bullosa. Pediatr Infect Dis J. 2023 Jun 1;42(6):510-514. doi: 10.1097/INF.0000000000003871. Epub 2023 Feb 14. PMID: 36795569.

IF (2022): 3,6 Q1  Pediatrics (23/130)

 

4) Lwin SM, McGrath JA. Restoring type VII collagen in skin. Med 2022 May 13;3(5):273-275. doi: 10.1016/j.medj.2022.04.008. Epub 2022 May 13.PMID: 35584643

IF (2022): 17  Q1  Medicine, research & experimental (2/190)

Open Access: https://www.sciencedirect.com/science/article/pii/S266663402200174X?via%3Dihub

 

5) Lozano Í, Bangueses R, Rodríguez I, Pevida M, Rodríguez-Aguilar R, Rodríguez D, Espasandín-Arias M, Llames S, Meana Á, Suárez A, Rodríguez-Carrio J. In-stent restenosis is associated with proliferative skin healing and specific immune and endothelial cell profiles: results from the RACHEL trial. Front Immunol. 2023 May 31;14:1138247. doi: 10.3389/fimmu.2023.1138247. PMID: 37325628; PMCID: PMC10265483.

IF (2022): 7,3 Q1 Immunology  (35/161)

Open Access: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265483/

 

6) Subramaniam KS, Antoniou MN, McGrath JA, Lwin SM. The potential of gene therapy for recessive dystrophic epidermolysis bullosa. Br J Dermatol. 2022 Apr;186(4):609-619. doi: 10.1111/bjd.20910. Epub 2022 Apr 1.PMID: 34862606

IF (2022): 10,3           Q1  Dermatology (3/70)

 

7) Prieto-Fernandez L, Villaronga MLA, Hermida-Prado F, Hijazi M, Montoro-Jimenez I, Pevida M, Llames S, Rodrigo JP, Cutillas P, Calvo F, Garcia-Pedrero JM, Alvarez-Teijeiro S. Driving role of head and neck cancer cell secretome on the invasion of stromal fibroblasts: Mechanistic insights by phosphoproteomics. Biomed Pharmacother. 2023 Feb;158:114176. doi: 10.1016/j.biopha.2022.114176. Epub 2023 Jan 9. PMID: 36916400.

IF (2022): 7,5 Q1 Pharmacology & Pharmacy  (22/278)

Open Access: https://www.sciencedirect.com/science/article/pii/S0753332222015657?via%3Dihub

 

8) Hervás-Salcedo R, Fernández-García M, Hernando-Rodríguez M, Suárez-Cabrera C, Bueren JA, Yáñez RM. Improved efficacy of mesenchymal stromal cells stably expressing CXCR4 and IL-10 in a xenogeneic graft versus host disease mouse model. Front Immunol. 2023 Feb 1;14:1062086. doi: 10.3389/fimmu.2023.1062086. PMID: 36817457; PMCID: PMC9929539.

IF (2022): 7,3 Q1  Immunology (35/161)

Open Access: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1062086/full

 

9) Chacón M, Vázquez N, Alonso-Alonso S, Persinal-Medina M, Llames S, Pevida M, Alcalde I, Merayo-Lloves J, Meana Á. Improved Tool for Predicting Skin Irritation on Reconstructed Human Epidermis Models Based on Electrochemical Impedance Spectroscopy. Biosensors (Basel). 2023 Jan 20;13(2):162. doi: 10.3390/bios13020162. PMID: 36831928; PMCID: PMC9953113.

IF: 5,4 Q1  Chemistry, Analytical (14/86)

Open Access: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953113/

 

10) García M, Bonafont J, Martínez-Palacios J, Xu R, Turchiano G, Svensson S, Thrasher AJ, Larcher F, Del Rio M, Hernández-Alcoceba R, Garín MI, Mencía Á, Murillas R. Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa by in vivo CRISPR-Cas9 delivery using adenoviral vectors.

Mol Ther Methods Clin Dev. 2022 27:96-108. PMID: 36212909 DOI: 10.1016/j.omtm.2022.09.005.

IF: 4,7 Q2 Medicine, Research & Experimental (54/136)

Open Access: https://www.sciencedirect.com/science/article/pii/S2329050122001309?via%3Dihub

e-archivos UC3M: https://e-archivo.uc3m.es/handle/10016/37201

 

11) Schmidt D, Díaz P, Muñoz D, Espinoza F, Nystrom A, Fuentes I, Ezquer M, Bennett DL, Calvo M.Pain. Characterisation of the pathophysiology of neuropathy and sensory dysfunction in a mouse model of recessive dystrophic epidermolysis bullosa. 2022 1;163(10):2052-2060. doi: 10.1097/j.pain.0000000000002599. Epub 2022 Jan 28.PMID: 35311752

IF: 7,4 Q1 Neurosciences (30/272)

 

12) O’Keeffe Ahern J, Lara-Sáez I, Zhou D, Murillas R, Bonafont J, Mencía Á, García M, Manzanares D, Lynch J, Foley, R., Xu, Q., Sigen, A., Larcher, F., Wang, W. Non-viral delivery of CRISPR–Cas9 complexes for targeted gene editing via a polymer delivery system. 2022 Gene Therapy 29:157–170 PMID: 34363036 DOI: 10.1038/s41434-021-00282-6.

IF: 5,1 Q1 Genetics & Heredity (31/171)

Open Access: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013665/

 

13) Gostyński A, Diercks GFH, Escamez MJ, Chandran NS, de Lucas R, Garcia-Martin A, Del Rio M, Bremer J, Bolling MC, Meana A, Llames SG, Schmidt E, Ludwig R, Jonkman MF, Pas HH, Pasmooij AMG. Natural Occurrence of Autoantibodies against Basement Membrane Proteins in Epidermolysis Bullosa. J Invest Dermatol. 2022 142(7):2014-2019.e3. doi: 10.1016/j.jid.2021.10.030. Epub 2021 Nov 26. PMID: 34843678.

IF: 6,5 Q1 (D1) Dermatology (6/70)

Open Access: https://www.sciencedirect.com/science/article/pii/S0022202X21025847?via%3Dihub

e-archivos UC3M: https://e-archivo.uc3m.es/handle/10016/37088

 

14) Segura-Bedmar I, Camino-Perdones D, Guerrero-Aspizua S. Exploring deep learning methods for recognizing rare diseases and their clinical manifestations from texts. BMC Bioinformatics 2022 6;23(1):263. PMID: 35794528.

IF: 3 Q2 Mathematical & Computational Biology (19/55)

Open Access: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258216/

 

15) Martínez-Santamaría L, Maseda R, de Arriba MDC, Membrilla JA, Sigüenza AI, Mascías J, García M, Quintana L, Esteban-Rodríguez I, Hernández-Fernández CP, Illera N, Duarte B, Guerrero-Aspizúa S, Woodley DT, Del Río M, de Lucas R, Larcher F, Escámez MJ. Evaluation of Systemic Gentamicin as Translational Readthrough Therapy for a Patient With Epidermolysis Bullosa Simplex With Muscular Dystrophy Owing to PLEC1 Pathogenic Nonsense Variants. JAMA Dermatol. 2022 158(4):439-443. PMID: 35234827.

IF: 10,9          Q1 (D1) Dermatology (2/70)

Open Access: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892370/

 

16) Persinal-Medina M, Llames S, Chacón M, Vázquez N, Pevida M, Alcalde I, Alonso-Alonso S, Martínez-López LM, Merayo-Lloves J, Meana Á. Polymerizable Skin Hydrogel for Full Thickness Wound Healing. Int J Mol Sci. 2022 23(9):4837. PMID: 35563225.

IF: 5,6 Q1  Biochemistry & Molecular Biology (66/285)

Open Access: https://www.mdpi.com/1422-0067/23/9/4837

 

17) Almeida J, Tenreiro M, Martinez-Santamaria L, Guerrero Aspizua S, Gisbert JP, Alves PM, Serra M, Baptista PM. Hallmarks of the human intestinal microbiome on liver maturation and function. 2022 J Hepatol. Mar;76(3):694-725 PMID: 34715263 DOI: 10.1016/j.jhep.2021.10.015.

IF: 25.7          Q1 (D1) Gastroenterology & Hepatology (4/93)

Open Access: https://www.sciencedirect.com/science/article/pii/S0168827821021528?via%3Dihub

 

18) Martínez-de Miguel C, Segura-Bedmar I, Chacón-Solano E, Guerrero-Aspizua S. The RareDis corpus: A corpus annotated with rare diseases, their signs and symptoms. J. Biomed Inform. 2022. 125:103961. PMID: 34879250.

IF: 4,5 Q2 Medical Informatics (12/31)

Open Access: https://www.sciencedirect.com/science/article/pii/S1532046421002902?via%3Dihub

e-archivos UC3M: https://e-archivo.uc3m.es/handle/10016/36462

 

19) Luque J, Mendes I, Gómez B, Morte B, López de Heredia M, Herreras E, Corrochano V, Bueren J, Gallano P, Artuch R, Fillat C, Pérez-Jurado LA, Montoliu L, Carracedo Á, Millán JM, Webb SM, Palau F, CIBERER Network: Carretero M, del Río M, Escámez MJ, Llames S... and Lapunzina P. CIBERER: Spanish national network for research on rare diseases: A highly productive collaborative initiative. Clin Genet. 2022. 101(5-6):481-493. PMID: 35060122

IF: 3,5 Q2 Genetics & Heredity (65/171)

Open Access: https://onlinelibrary.wiley.com/doi/10.1111/cge.14113

 

20) Ramos-Espinosa O, Mata-Espinosa D, Francisco-Cruz A, López-Torres MO, Hernández-Bazán S, Barrios-Payán J, Marquina-Castillo B, Carretero M, Del Río M, Hernández-Pando R.  Immunotherapeutic effect of adenovirus encoding antimicrobial peptides in experimental pulmonary tuberculosis.
2021. Journal of Leukocyte Biology. 110(5):951-963 PMID: 33682193 DOI: 10.1002/JLB.4MA0920-627R

IF: 5,5 Q2 Immunology (57/161)

 

21) Potrony M, Haddad TS, Tell-Martí G, Gimenez-Xavier P, Leon C, Pevida M, Mateu J, Badenas C, Carrera C, Malvehy J, Aguilera P, Llames S, Escámez MJ, Puig-Butillé JA, Del Río M, Puig S. DNA Repair and Immune Response Pathways Are Deregulated in Melanocyte-Keratinocyte Co-cultures Derived From the Healthy Skin of Familial Melanoma Patients. 2021. Frontiers in Medicine. 8: 692341 PMID: 34660619 DOI: 10.3389/fmed.2021.692341.

IF: 3,9  Q2 Medicine, General & Internal (58/169)

Open Access: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517393/

e-archivos UC3M: https://e-archivo.uc3m.es/handle/10016/34433

 

 

22) Nyström A, Bruckner-Tuderman L, Kiritsi D. Dystrophic Epidermolysis Bullosa: Secondary Disease Mechanisms and Disease Modifiers. Front Genet. 2021 28;12:737272. doi: 10.3389/fgene.2021.737272. eCollection 2021.PMID: 34650598 

IF: 3,7 Q2 Genetics & Heredity (60/171)

Open Access: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505774/

 

23) Bonafont J, Mencía A, Chacón-Solano E, Srifa W, Vaidyanathan S, Romano R, Garcia M, Hervás-Salcedo R, Ugalde L, Duarte B, Porteus MH, Del Río M, Larcher F, Murillas R. Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing. Molecular Therapy. 2021. 29(6):2008-2018. PMID: 33609734. doi: 10.1016/j.ymthe.2021.02.019.

IF: 12,91                    Q1 (D1) Genetics & Heridity (7/175)

Open Access: https://www.sciencedirect.com/science/article/pii/S1525001621000861?via%3Dihub

e-archivos UC3M: https://e-archivo.uc3m.es/handle/10016/37727

 

24) Hervás-Salcedo R, Fernández-García M, Hernando-Rodríguez M, Quintana-Bustamante O, Segovia JC, Alvarez-Silva M, García-Arranz M, Minguez P, Del Pozo V, de Alba MR, García-Olmo D, Ayuso C, Lamana ML, Bueren JA, Yañez RM. Enhanced anti-inflammatory effects of mesenchymal stromal cells mediated by the transient ectopic expression of CXCR4 and IL10. Stem Cell Res Ther. 2021 12(1):124. doi: 10.1186/s13287-021-02193-0. PMID: 33579367; PMCID: PMC7881581.

IF: 7,5 Q1 Cell & Tissue Engineering (4/29)

Open Access: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881581/ 

 

​

​

​

 

 

​